1. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

TGFb1 Antibody

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

7

Inhibitory Antibodies

4

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99305
    Metelimumab
    3 Publications Verification

    CAT-192; Anti-TGFb1 Recombinant Antibody

    TGF-β Receptor Inflammation/Immunology
    Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that can selectively neutralize TGFβ1 .
    Metelimumab
  • HY-P990009

    NIS-793

    TGF-beta/Smad Cancer
    Nisevokitug (NIS-793) is a human, IgG2λ antibody targeting TGF-β (TGFB1/TGFB2). Nisevokitug is expressed by CHO-K1 cells .
    Nisevokitug
  • HY-P990517

    TGF-beta/Smad Inflammation/Immunology
    Anti-TGFb1 Antibody is a humanized antibody expressed in CHO cells that targets TGFb1. The Anti-TGFb1 Antibody has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TGFb1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-TGFb1 Antibody
  • HY-P99606

    ZTS-00521426

    TGF-beta/Smad Inflammation/Immunology
    Cirevetmab (ZTS-00521426) is an immunoglobulin G2-kappa, Canis lupus familiaris TGFB1 caninized monoclonal antibody. Cirevetmab is an immunomodulator .
    Cirevetmab
  • HY-P991382

    TGF-β Receptor Cancer
    SAR-439459 is a human monoclonal antibody (mAb) targeting TGFB1/TGFβ-1. SAR-439459 blocks TGFβ-mediated pSMAD signaling, and suppression of T cells and NK cells. SAR-439459 has anti-tumor activity .
    SAR-439459
  • HY-P991383

    TGF-β Receptor Metabolic Disease
    LY2382770 is a human monoclonal antibody (mAb) targeting TGFB1. LY2382770 can be used in dabetic nephropathies research .
    LY2382770
  • HY-P991950

    TGF-beta/Smad Inflammation/Immunology
    SHR-1906 is a selective fully humanized monoclonal IgG1 inhibitory antibody targeting CTGF. SHR-1906 specifically binds to CTGF, thereby blocking the interaction between CTGF and TGF-B1 with an inhibition rate of 55%. SHR-1906increases the survival rate in a pulmonary fibrosis model by reducing TGF-β1 levels and inhibiting fibrotic lesions in lung tissue in Bleomycin (HY-108345)-induced pulmonary fibrosis.SHR-1906 can be used for pulmonary fibrosis (IPF) research. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    SHR-1906

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: